Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01581424 · ClinicalTrials.gov registry record

Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study

A clinical trial of Fabry Disease, sponsored by University of Minnesota.

Recruiting
Registry status
50
Enrollment target
2
Study locations

NCT01581424: Recruiting study of Fabry Disease, sponsored by University of Minnesota.

NCT01581424 is a study of Fabry Disease that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 50 participants, below the 541-participant average among 32 other Fabry Disease trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01581424, a study of Fabry Disease, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
50 participants
Enrollment target
2
Study locations

Study Summary

The investigators will perform a study with two major components. The first is a natural history study of untreated Fabry patients. This study component will detail kidney microscopic structural changes in Fabry patients before starting enzyme replacement therapy and will correlate these changes with kidney function, including glomerular filtration rate and urinary albumin excretion rate. The investigators will perform studies on samples obtained at baseline, or before enzyme replacement therapy is initiated. The goal of our study is to find kidney microscopic changes in the biopsies that are associated with kidney disfunction. Our hypotheses for this study are: 1. Much of the natural history of Fabry renal structural changes will occur without detectable renal functional alterations. 2. Structural changes associated with the initial onset of proteinuria and those associated with the subsequent progressive loss of filtration function will differ and will be best described by non-linear models. 3. There will be sufficient precision of Fabry renal structural-functional relationships to support renal structure as an acceptable clinical trial surrogate endpoint for later renal functional deterioration. The second component examines the effects of age and gender at start of enzyme replacement therapy (ERT), as well as dosage levels of ERT on the renal cellular clearance of GL3 from Fabry patients by comparing baseline to follow-up kidney biopsies performed 5, 11, and 60 months later, with all comparisons matched for ERT treatment duration. Our hypotheses for this component of the study are as follows: 1. Enzyme Replacement Therapy(ERT) instituted at younger ages is more effective in reducing podocytes(PC),distal tubular cells(DTC),and arterial smooth muscle cells (ASMC)GL-3 than in older Fabry patients. 2. Earlier institution of ERT will stabilize PC numbers while later ERT institution, especially in proteinuric adults, may not prevent progressive decline in PC number

Primary Outcome

Renal function measurements for the cross sectional natural history component will be urine protein excretion and measured/estimated GFR. Renal biopsies will provide estimates of the amount of GL-3 in various kidney structures. We will determine which structural parameter or composite of structural parameters is most closely associated with kidney function. For renal structural responses (changes) with ERT the primary outcome will the magnitude of reduction in podocyte GL-3 per glomerulus after

Conditions Studied

Study Locations (2)

Minnesota

  • University of Minnesota - Minneapolis
  • Universtity of Minnesota, Department of Pediatric Nephrology - Minneapolis

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-10
Est. Completion 2030-07-31
University of Minnesota

966 total trials

What NCT01581424 shows while recruiting

NCT01581424 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 541-participant average among 32 other Fabry Disease trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01581424 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT01581424 about?

NCT01581424 is a clinical study titled "Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study". The investigators will perform a study with two major components. The first is a natural history study of untreated Fabry patients. This study component will detail kidney microscopic structural changes in Fabry patients before starting enzyme replacement therapy and will correlate these changes wit...

What is the current status of trial NCT01581424?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2010-10. Estimated completion is 2030-07-31.

What conditions does trial NCT01581424 study?

This clinical trial studies the following conditions: Fabry Disease.

Who is sponsoring clinical trial NCT01581424?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01581424 being conducted?

This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fabry Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01581424's enrollment target sits among peer trials

50 13th of 32 higher than 20 of 32 other Fabry Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fabry Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01581424, the US trial registry maintained by the National Library of Medicine. NCT01581424 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.